Key information

🔎 Fund Overview

4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company. The Company is developing a diverse pipeline of product candidates for both large market and rare diseases, including patient populations that other genetic medicines are unable to address. The Company's initial product candidates are focused on therapeutic areas, such as ophthalmology, pulmonology, and cardiology. The Company's five product candidates include 4D-150, 4D-710, 4D-125, 4D-110, and 4D-310. 4D-150 is used for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). 4D-710 is used for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations). 4D-310 is used for the treatment of Fabry disease cardiomyopathy. 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP). 4D-110 is used for the treatment of choroideremia.